Document is current

Article History

Received: 16 April 2022

Accepted: 26 July 2022

First Online: 9 August 2022

Declarations

:

: This study was approved by the Ethics Committee of Japanese Red Cross Kyoto Daiichi Hospital. In this study, we evaluated only information that is collected in usual medical practice, and we substituted the agreement acquisition in the document with posting based on ‘Ethical Guidelines for Epidemiological Research’ (in Japan).

: Not applicable.

: WF has received speaker’s fee from Chugai Pharmaceutical Co., Eisai Co., Ltd., Eli Lilly Japan K.K., AbbVie GK, Ono Pharmaceutical Co. Ltd., Astellas Pharma Inc., UCB Japan Co. Ltd., Pfizer Japan Inc., Asahikasei Pharma Co., Daiichi-Sankyo Inc., Mitsubishi Tanabe Pharma Co. (less than $10,000 each). AO received speaker’s fees from AbbVie GK, Chugai, Eizai Co., Ltd., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Inc., Astellas Pharma Inc., Mitsubishi-Tanabe Pharma Co., Pfizer Japan Inc., Asahikasei Pharma Co., Novartis, Gilead Science Inc., Janssen Pharmaceutical K.K., GlaxoSmithKline K.K., and Eli Lilly Japan K.K. (less than $10,000 each). SM has received speaker’s fee from Bristol Myers Squibb Co. (less than $10,000). MK (Masataka Kohno) has received speaker’s fee from AbbVie GK, Astellas Pharma Inc., Bristol Myers Squibb Co., Chugai Pharmaceutical Co., Ltd. Daiichi Sankyo Co., Eli Lilly Japan K.K, Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Asahikasei Pharma Co., Pfizer Japan Inc., Sanofi Japan K.K., Nippon Boehringer Ingelheim Co. Ltd., UCB Japan Co. Ltd., Eisai Co. Ltd., GlaxoSmithKline K.K. (less than $10,000 each). YK has received research grants from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Corp., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. YK has received speaker’s fee from AbbVie GK, Ayumi Pharmaceutical Corp., Boehringer Ingelheim Japan, Inc., , Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. (less than $10,000 each). MK (Masatoshi Kadoya), TY, YI, AS, HK, and KU have no competing interests.